Detalhe da pesquisa
1.
Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
Int J Cancer
; 148(8): 1910-1918, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33105030
2.
To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma.
Cancer
; 127(13): 2333-2341, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844296
3.
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
BMC Cancer
; 20(1): 304, 2020 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32293341
4.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol
; 20(9): 1239-1251, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345627
5.
Melanoma of the Vulva and Vagina: Surgical Management and Outcomes Based on a Clinicopathologic Reviewof 68 Cases.
J Obstet Gynaecol Can
; 41(6): 762-771, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30391279
6.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Lancet
; 390(10105): 1853-1862, 2017 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28822576
7.
Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
Ann Surg Oncol
; 22(6): 1950-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25366584
8.
Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review.
Surg Oncol
; 54: 102077, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657486
9.
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.
Cancer Med
; 12(10): 11451-11461, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999965
10.
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
J Clin Oncol
; 41(24): 3998-4003, 2023 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37348035
11.
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
J Clin Oncol
; 41(1): 75-85, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35867951
12.
A tailored approach to horizon scanning for cancer medicines.
J Cancer Policy
; 38: 100441, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38008488
13.
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?
Am Soc Clin Oncol Educ Book
; 42: 1-7, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658502
14.
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Cancer Discov
; 12(3): 644-653, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34764195
15.
Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma.
JCO Oncol Pract
; 17(11): e1631-e1638, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33780266
16.
Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.
Curr Oncol
; 28(5): 3537-3553, 2021 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34590600
17.
Restructuring Skin Cancer Care in Ontario: A Provincial Plan.
Curr Oncol
; 28(2): 1183-1196, 2021 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33809399
18.
Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients.
Cancers (Basel)
; 13(9)2021 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34068774
19.
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
J Immunother Cancer
; 9(5)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963015
20.
Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.
Breast Cancer Res Treat
; 123(3): 837-42, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20697802